UNITED THERAPEUTICS CORP (UTHR) Stock Fundamental Analysis

NASDAQ:UTHR • US91307C1027

473.42 USD
-7.1 (-1.48%)
At close: Feb 20, 2026
472 USD
-1.42 (-0.3%)
After Hours: 2/20/2026, 6:39:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

7

Overall UTHR gets a fundamental rating of 7 out of 10. We evaluated UTHR against 521 industry peers in the Biotechnology industry. UTHR gets an excellent profitability rating and is at the same time showing great financial health properties. UTHR has a correct valuation and a medium growth rate. With these ratings, UTHR could be worth investigating further for quality investing!.


Dividend Valuation Growth Profitability Health

9

1. Profitability

1.1 Basic Checks

  • UTHR had positive earnings in the past year.
  • In the past year UTHR had a positive cash flow from operations.
  • Each year in the past 5 years UTHR has been profitable.
  • In the past 5 years UTHR always reported a positive cash flow from operatings.
UTHR Yearly Net Income VS EBIT VS OCF VS FCFUTHR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

1.2 Ratios

  • UTHR has a Return On Assets of 17.30%. This is amongst the best in the industry. UTHR outperforms 95.97% of its industry peers.
  • UTHR's Return On Equity of 19.30% is amongst the best of the industry. UTHR outperforms 95.20% of its industry peers.
  • UTHR has a better Return On Invested Capital (17.33%) than 96.93% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for UTHR is below the industry average of 18.69%.
  • The 3 year average ROIC (14.96%) for UTHR is below the current ROIC(17.33%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 17.3%
ROE 19.3%
ROIC 17.33%
ROA(3y)14%
ROA(5y)12.47%
ROE(3y)16.72%
ROE(5y)15.47%
ROIC(3y)14.96%
ROIC(5y)13.31%
UTHR Yearly ROA, ROE, ROICUTHR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30 40

1.3 Margins

  • UTHR has a Profit Margin of 40.65%. This is amongst the best in the industry. UTHR outperforms 97.12% of its industry peers.
  • UTHR's Profit Margin has improved in the last couple of years.
  • Looking at the Operating Margin, with a value of 48.65%, UTHR belongs to the top of the industry, outperforming 99.62% of the companies in the same industry.
  • UTHR's Operating Margin has improved in the last couple of years.
  • UTHR's Gross Margin of 88.59% is amongst the best of the industry. UTHR outperforms 90.79% of its industry peers.
  • In the last couple of years the Gross Margin of UTHR has remained more or less at the same level.
Industry RankSector Rank
OM 48.65%
PM (TTM) 40.65%
GM 88.59%
OM growth 3Y7.2%
OM growth 5Y2.85%
PM growth 3Y13.74%
PM growth 5YN/A
GM growth 3Y-1.27%
GM growth 5Y-0.58%
UTHR Yearly Profit, Operating, Gross MarginsUTHR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. Health

2.1 Basic Checks

  • UTHR has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • UTHR has less shares outstanding than it did 1 year ago.
  • UTHR has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, UTHR has an improved debt to assets ratio.
UTHR Yearly Shares OutstandingUTHR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
UTHR Yearly Total Debt VS Total AssetsUTHR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

  • An Altman-Z score of 19.47 indicates that UTHR is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of UTHR (19.47) is better than 89.06% of its industry peers.
  • UTHR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 19.47
ROIC/WACC2
WACC8.66%
UTHR Yearly LT Debt VS Equity VS FCFUTHR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B 6B

2.3 Liquidity

  • A Current Ratio of 6.40 indicates that UTHR has no problem at all paying its short term obligations.
  • UTHR has a Current ratio of 6.40. This is in the better half of the industry: UTHR outperforms 65.07% of its industry peers.
  • UTHR has a Quick Ratio of 6.07. This indicates that UTHR is financially healthy and has no problem in meeting its short term obligations.
  • UTHR's Quick ratio of 6.07 is fine compared to the rest of the industry. UTHR outperforms 64.49% of its industry peers.
Industry RankSector Rank
Current Ratio 6.4
Quick Ratio 6.07
UTHR Yearly Current Assets VS Current LiabilitesUTHR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • UTHR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.90%, which is quite good.
  • Measured over the past years, UTHR shows a quite strong growth in Earnings Per Share. The EPS has been growing by 16.88% on average per year.
  • The Revenue has grown by 13.50% in the past year. This is quite good.
  • The Revenue has been growing by 14.71% on average over the past years. This is quite good.
EPS 1Y (TTM)15.9%
EPS 3Y34.86%
EPS 5Y16.88%
EPS Q2Q%12.05%
Revenue 1Y (TTM)13.5%
Revenue growth 3Y19.52%
Revenue growth 5Y14.71%
Sales Q2Q%6.76%

3.2 Future

  • Based on estimates for the next years, UTHR will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.76% on average per year.
  • UTHR is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.22% yearly.
EPS Next Y12.48%
EPS Next 2Y9.45%
EPS Next 3Y8.97%
EPS Next 5Y11.76%
Revenue Next Year11.46%
Revenue Next 2Y8.55%
Revenue Next 3Y9.27%
Revenue Next 5Y11.22%

3.3 Evolution

  • The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
UTHR Yearly Revenue VS EstimatesUTHR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
UTHR Yearly EPS VS EstimatesUTHR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10 20 30 40 50

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 17.94 indicates a rather expensive valuation of UTHR.
  • 95.01% of the companies in the same industry are more expensive than UTHR, based on the Price/Earnings ratio.
  • Compared to an average S&P500 Price/Earnings ratio of 26.99, UTHR is valued a bit cheaper.
  • The Price/Forward Earnings ratio is 16.06, which indicates a correct valuation of UTHR.
  • 95.59% of the companies in the same industry are more expensive than UTHR, based on the Price/Forward Earnings ratio.
  • UTHR is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 28.06, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 17.94
Fwd PE 16.06
UTHR Price Earnings VS Forward Price EarningsUTHR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • 96.93% of the companies in the same industry are more expensive than UTHR, based on the Enterprise Value to EBITDA ratio.
  • 95.97% of the companies in the same industry are more expensive than UTHR, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 18.26
EV/EBITDA 10.28
UTHR Per share dataUTHR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 50 100 150

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • UTHR has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)1.44
PEG (5Y)1.06
EPS Next 2Y9.45%
EPS Next 3Y8.97%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for UTHR!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

UNITED THERAPEUTICS CORP

NASDAQ:UTHR (2/20/2026, 6:39:00 PM)

After market: 472 -1.42 (-0.3%)

473.42

-7.1 (-1.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-29
Earnings (Next)02-25
Inst Owners98.84%
Inst Owner Change-3.43%
Ins Owners1.84%
Ins Owner Change-2.9%
Market Cap20.39B
Revenue(TTM)3.13B
Net Income(TTM)1.27B
Analysts80.95
Price Target539.51 (13.96%)
Short Float %4.1%
Short Ratio4.45
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-5.9%
Min EPS beat(2)-9.46%
Max EPS beat(2)-2.35%
EPS beat(4)0
Avg EPS beat(4)-4.02%
Min EPS beat(4)-9.46%
Max EPS beat(4)-0.45%
EPS beat(8)2
Avg EPS beat(8)-2.47%
EPS beat(12)5
Avg EPS beat(12)-3.15%
EPS beat(16)7
Avg EPS beat(16)-2.98%
Revenue beat(2)0
Avg Revenue beat(2)-3.23%
Min Revenue beat(2)-3.81%
Max Revenue beat(2)-2.65%
Revenue beat(4)1
Avg Revenue beat(4)-0.39%
Min Revenue beat(4)-3.81%
Max Revenue beat(4)6.71%
Revenue beat(8)5
Avg Revenue beat(8)1.56%
Revenue beat(12)7
Avg Revenue beat(12)1.27%
Revenue beat(16)9
Avg Revenue beat(16)1.26%
PT rev (1m)3.72%
PT rev (3m)7.99%
EPS NQ rev (1m)-1.25%
EPS NQ rev (3m)-3.54%
EPS NY rev (1m)0.23%
EPS NY rev (3m)-1.46%
Revenue NQ rev (1m)-0.24%
Revenue NQ rev (3m)-0.16%
Revenue NY rev (1m)-0.06%
Revenue NY rev (3m)-0.09%
Valuation
Industry RankSector Rank
PE 17.94
Fwd PE 16.06
P/S 6.52
P/FCF 18.26
P/OCF 13.1
P/B 3.09
P/tB 3.15
EV/EBITDA 10.28
EPS(TTM)26.39
EY5.57%
EPS(NY)29.47
Fwd EY6.22%
FCF(TTM)25.93
FCFY5.48%
OCF(TTM)36.14
OCFY7.63%
SpS72.65
BVpS153.05
TBVpS150.34
PEG (NY)1.44
PEG (5Y)1.06
Graham Number301.46
Profitability
Industry RankSector Rank
ROA 17.3%
ROE 19.3%
ROCE 22.37%
ROIC 17.33%
ROICexc 29.21%
ROICexgc 30.07%
OM 48.65%
PM (TTM) 40.65%
GM 88.59%
FCFM 35.69%
ROA(3y)14%
ROA(5y)12.47%
ROE(3y)16.72%
ROE(5y)15.47%
ROIC(3y)14.96%
ROIC(5y)13.31%
ROICexc(3y)29.18%
ROICexc(5y)24.89%
ROICexgc(3y)30.03%
ROICexgc(5y)25.71%
ROCE(3y)19.31%
ROCE(5y)17.18%
ROICexgc growth 3Y23.22%
ROICexgc growth 5Y4.92%
ROICexc growth 3Y22.46%
ROICexc growth 5Y5.97%
OM growth 3Y7.2%
OM growth 5Y2.85%
PM growth 3Y13.74%
PM growth 5YN/A
GM growth 3Y-1.27%
GM growth 5Y-0.58%
F-Score8
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 533.09%
Cap/Sales 14.06%
Interest Coverage 81.39
Cash Conversion 96.99%
Profit Quality 87.79%
Current Ratio 6.4
Quick Ratio 6.07
Altman-Z 19.47
F-Score8
WACC8.66%
ROIC/WACC2
Cap/Depr(3y)347.88%
Cap/Depr(5y)280.91%
Cap/Sales(3y)8.54%
Cap/Sales(5y)7.36%
Profit Quality(3y)85.86%
Profit Quality(5y)98.64%
High Growth Momentum
Growth
EPS 1Y (TTM)15.9%
EPS 3Y34.86%
EPS 5Y16.88%
EPS Q2Q%12.05%
EPS Next Y12.48%
EPS Next 2Y9.45%
EPS Next 3Y8.97%
EPS Next 5Y11.76%
Revenue 1Y (TTM)13.5%
Revenue growth 3Y19.52%
Revenue growth 5Y14.71%
Sales Q2Q%6.76%
Revenue Next Year11.46%
Revenue Next 2Y8.55%
Revenue Next 3Y9.27%
Revenue Next 5Y11.22%
EBIT growth 1Y12.9%
EBIT growth 3Y28.12%
EBIT growth 5Y17.97%
EBIT Next Year18.45%
EBIT Next 3Y8.03%
EBIT Next 5Y-4.6%
FCF growth 1Y46.07%
FCF growth 3Y31.3%
FCF growth 5YN/A
OCF growth 1Y62.87%
OCF growth 3Y30.42%
OCF growth 5YN/A

UNITED THERAPEUTICS CORP / UTHR FAQ

What is the fundamental rating for UTHR stock?

ChartMill assigns a fundamental rating of 7 / 10 to UTHR.


What is the valuation status of UNITED THERAPEUTICS CORP (UTHR) stock?

ChartMill assigns a valuation rating of 6 / 10 to UNITED THERAPEUTICS CORP (UTHR). This can be considered as Fairly Valued.


Can you provide the profitability details for UNITED THERAPEUTICS CORP?

UNITED THERAPEUTICS CORP (UTHR) has a profitability rating of 9 / 10.


What are the PE and PB ratios of UNITED THERAPEUTICS CORP (UTHR) stock?

The Price/Earnings (PE) ratio for UNITED THERAPEUTICS CORP (UTHR) is 17.94 and the Price/Book (PB) ratio is 3.09.


What is the expected EPS growth for UNITED THERAPEUTICS CORP (UTHR) stock?

The Earnings per Share (EPS) of UNITED THERAPEUTICS CORP (UTHR) is expected to grow by 12.48% in the next year.